184 related articles for article (PubMed ID: 38128605)
1. Unmet needs in β-thalassemia and the evolving treatment landscape.
Njeim R; Naouss B; Bou-Fakhredin R; Haddad A; Taher A
Transfus Clin Biol; 2024 Feb; 31(1):48-55. PubMed ID: 38128605
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
3. 2021 update on clinical trials in β-thalassemia.
Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
[TBL] [Abstract][Full Text] [Related]
4. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
Motta I; Bou-Fakhredin R; Taher AT; Cappellini MD
Drugs; 2020 Jul; 80(11):1053-1063. PubMed ID: 32557398
[TBL] [Abstract][Full Text] [Related]
5. Beta Thalassemia: Monitoring and New Treatment Approaches.
Khandros E; Kwiatkowski JL
Hematol Oncol Clin North Am; 2019 Jun; 33(3):339-353. PubMed ID: 31030806
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapies in β-thalassemia: toward a new era in management.
Bou-Fakhredin R; Tabbikha R; Daadaa H; Taher AT
Expert Opin Emerg Drugs; 2020 Jun; 25(2):113-122. PubMed ID: 32249632
[TBL] [Abstract][Full Text] [Related]
7. Cardiac complications in thalassemia throughout the lifespan: Victories and challenges.
Wood JC
Ann N Y Acad Sci; 2023 Dec; 1530(1):64-73. PubMed ID: 37902424
[TBL] [Abstract][Full Text] [Related]
8. Non-transfusion Dependent Thalassemias: A Developing Country Perspective.
Mukherjee S; Das RR; Raghuwanshi B
Curr Pediatr Rev; 2015; 11(2):87-97. PubMed ID: 26133180
[TBL] [Abstract][Full Text] [Related]
9. Emerging Therapies in β-Thalassemia.
Bou-Fakhredin R; Kuo KHM; Taher AT
Hematol Oncol Clin North Am; 2023 Apr; 37(2):449-462. PubMed ID: 36907614
[TBL] [Abstract][Full Text] [Related]
10. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
Shash H
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295656
[TBL] [Abstract][Full Text] [Related]
11. Morbidities in non-transfusion-dependent thalassemia.
Saliba AN; Taher AT
Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
[TBL] [Abstract][Full Text] [Related]
12. Recent trends in treatment of thalassemia.
El-Beshlawy A; El-Ghamrawy M
Blood Cells Mol Dis; 2019 May; 76():53-58. PubMed ID: 30792169
[TBL] [Abstract][Full Text] [Related]
13. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.
Sleiman J; Tarhini A; Bou-Fakhredin R; Saliba AN; Cappellini MD; Taher AT
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316681
[TBL] [Abstract][Full Text] [Related]
14. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.
Di Modica SM; Tanzi E; Olivari V; Lidonnici MR; Pettinato M; Pagani A; Tiboni F; Furiosi V; Silvestri L; Ferrari G; Rivella S; Nai A
Am J Hematol; 2022 Oct; 97(10):1324-1336. PubMed ID: 36071579
[TBL] [Abstract][Full Text] [Related]
15. Alpha- and Beta-thalassemia: Rapid Evidence Review.
Baird DC; Batten SH; Sparks SK
Am Fam Physician; 2022 Mar; 105(3):272-280. PubMed ID: 35289581
[TBL] [Abstract][Full Text] [Related]
16. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
[TBL] [Abstract][Full Text] [Related]
17. Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia.
Cappellini MD; Taher AT; Verma A; Shah F; Hermine O
Blood Rev; 2023 May; 59():101039. PubMed ID: 36577601
[TBL] [Abstract][Full Text] [Related]
18. Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia.
Hamed EM; Meabed MH; Aly UF; Hussein RRS
Curr Drug Targets; 2019; 20(16):1603-1623. PubMed ID: 31362654
[TBL] [Abstract][Full Text] [Related]
19. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
Asadov C; Alimirzoeva Z; Mammadova T; Aliyeva G; Gafarova S; Mammadov J
Int J Hematol; 2018 Jul; 108(1):5-21. PubMed ID: 29380178
[TBL] [Abstract][Full Text] [Related]
20. Iron overload in thalassemia: different organs at different rates.
Taher AT; Saliba AN
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
